A Phase 1/1b open-label dose-escalation and dose-expansion trial to evaluate the safety, tolerability, PK, PD, and clinical activity of etrumadenant + mFOLFOX in participants with gastroesophageal cancer or colorectal cancer.
Key Eligibility Criteria
- They have histologically confirmed colorectal cancer that is metastatic, advanced, or recurrent with progression
- Participants for whom mFOLFOX is considered appropriate therapy
- Oxaliplatin-based therapy was not the most recent regimen prior to enrolling in the trial, except if prior oxaliplatin-based therapy was received in the adjuvant setting and completed ≥ 6 months prior to trial enrollment